Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from RxSight ( (RXST) ).
On December 16, 2025, RxSight Chief Financial Officer Shelley Thunen notified the company she would transition out of her role as CFO and principal financial and accounting officer, effective upon the appointment of her successor or by January 31, 2026. Under a planned transition and consulting arrangement, Thunen will receive her base salary through the transition date, remain eligible for an annual cash bonus based on 2025 corporate performance, and continue to vest in her stock options while she provides transition services as a consultant through a term scheduled to run until December 31, 2026, compensated via monthly retainers for early 2026 and an hourly fee. In a December 22, 2025 press release, RxSight’s leadership credited Thunen, who has served the company for nearly a decade, with shaping its financial strategy, guiding it through its 2021 IPO, and helping drive its evolution from a pre-commercial business to one with more than 1,100 Light Delivery Devices in the field and over 250,000 procedures performed, underscoring the significance of the CFO transition for investors and other stakeholders while signaling continuity through her ongoing advisory role.
The most recent analyst rating on (RXST) stock is a Hold with a $12.50 price target. To see the full list of analyst forecasts on RxSight stock, see the RXST Stock Forecast page.
Spark’s Take on RXST Stock
According to Spark, TipRanks’ AI Analyst, RXST is a Neutral.
RxSight’s overall stock score is primarily influenced by its financial challenges, including negative profitability and revenue decline. While technical indicators show some positive momentum, the valuation remains unattractive due to the negative P/E ratio. The earnings call provided mixed signals with improvements in certain areas but highlighted significant revenue and net loss challenges.
To see Spark’s full report on RXST stock, click here.
More about RxSight
RxSight, Inc., based in Aliso Viejo, California, is an ophthalmic medical device company focused on providing customized vision to patients following cataract surgery. Its flagship RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens, Light Delivery Device and related accessories, is the first and only commercially available intraocular lens technology that can be adjusted after surgery, allowing physicians to fine-tune patients’ vision post-operatively.
Average Trading Volume: 782,744
Technical Sentiment Signal: Hold
Current Market Cap: $494.6M
Find detailed analytics on RXST stock on TipRanks’ Stock Analysis page.